Clinical Trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-21.
Trial Details
NCT Number NCT07375524
Lead Sponsor Shanghai Escugen Biotechnology Co., Ltd
Conditions Primary Sjögren Syndrome
Enrollment 40 participants
Start Date 2026-03-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-03